Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 3 complete abstracts (449 words), 9 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: B Lymphocytes; B-Cells, Lymphocyte; B-Cell, Lymphocyte; B Cells, Lymphocyte; Lymphocyte B-Cell; Lymphocyte B-Cells; B-Lymphocyte; B Lymphocyte.
Where it fits in the MeSH classification
- Broader topics
- Antibody-Producing Cells; Lymphocytes
- Narrower topics
- B-Lymphocyte Subsets; Plasma Cells; Precursor Cells, B-Lymphoid
- See also
- Lymphocyte Cooperation; Germinal Center
Research landscape
PubMed indexes 110,431 records tagged with the MeSH heading “B-Lymphocytes” (counts retrieved 2026-10-31). 13,574 of them (12.3%) were published from 2020 onward, and the busiest period so far is through 1999 with 51,989 records.
Reviews account for 15,037 records (13.6%) and meta-analyses for 67. Randomized controlled trials number 505 (0.5%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 51,989 |
| 2000-2009 | 20,260 |
| 2010-2019 | 24,608 |
| 2020 onward | 13,574 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 15,037 | 13.6% |
| Meta-analyses | 67 | 0.1% |
| Randomized controlled trials | 505 | 0.5% |
Method: PubMed query "B-Lymphocytes"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in anatomy and physiology
Anatomy describes how body structures are built and physiology describes how they normally work, so most findings here are descriptive or mechanistic rather than evidence about treatment. Much of what is known comes from dissection, imaging, tissue studies and experiments in animals, and measurements in healthy volunteers can differ from those in people with disease or at different ages. Normal ranges vary between individuals and populations. Check whether a result was measured in people or in another species, the age and health of the participants, and the method used.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Replaying germinal center evolution on a quantified affinity landscape | 2026 | Research article Design not recorded in structured metadata | 20 | cc by PMID 42248140 · DOI · PMC13360575 |
| Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development | 2026 | Research article Design not recorded in structured metadata | 18 | cc by PMID 41686912 · DOI · PMC13015429 |
| Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections | 2026 | Research article Design not recorded in structured metadata | 6 | cc by PMID 42097138 · DOI · PMC13639993 |
Replaying germinal center evolution on a quantified affinity landscape [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Darwinian evolution of immunoglobulin genes within germinal centers (GCs) underlies the progressive increase in antibody affinity following antigen exposure.
- Closing excerpt
- We infer a fitness landscape that quantitatively recapitulates the affinity maturation trajectory of our clone and find that apparent features of GC selection, such as permissiveness to low-affinity lineages and rapid plateauing of affinity, are likely artifacts of survivorship biases that distort our view of how B cell affinity progresses over time.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (148 words)
Darwinian evolution of immunoglobulin genes within germinal centers (GCs) underlies the progressive increase in antibody affinity following antigen exposure. Whereas the cellular mechanics of how competition between B cells increases affinity are well established, the evolutionary dynamics of this process are less clear. We developed an experimental evolution model in which we "replay" over one hundred monoclonal GC reactions, assigning affinities to each cell using deep mutational scanning. Our data reveal how GCs achieve predictable outcomes by means of noisy but persistent selection on an affinity landscape whose exploration is heavily constrained by somatic hypermutation biases. We infer a fitness landscape that quantitatively recapitulates the affinity maturation trajectory of our clone and find that apparent features of GC selection, such as permissiveness to low-affinity lineages and rapid plateauing of affinity, are likely artifacts of survivorship biases that distort our view of how B cell affinity progresses over time.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42248140 · DOI · PMC13360575
Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Broadly neutralizing antibodies (bNAbs) are rarely elicited during HIV-1 infection.
- Closing excerpt
- These results indicate that efficiency of B cell priming, and not complexities in Env-guided affinity maturation, is a primary obstacle to V2 apex bNAb elicitation in SHIV-infected macaques and identify specific HIV-1 Envs to advance as vaccine platforms.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (150 words)
Broadly neutralizing antibodies (bNAbs) are rarely elicited during HIV-1 infection. To identify obstacles to bNAb development, we longitudinally studied 122 rhesus macaques infected by 1 of 16 different simian-human immunodeficiency viruses (SHIVs). We identified the V2 apex region of the envelope (Env) as the most common bNAb target and a subset of Envs that preferentially elicited these antibodies. In 10 macaques, we delineated Env-antibody coevolution from B cell priming to bNAb development. Antibody phylogenies revealed permissive developmental pathways guided by evolving Envs that contained few mutations in or near the V2 apex C-strand, which were a sensitive indicator of apex-targeted responses. The absence of such mutations reflected a failure in bNAb priming. These results indicate that efficiency of B cell priming, and not complexities in Env-guided affinity maturation, is a primary obstacle to V2 apex bNAb elicitation in SHIV-infected macaques and identify specific HIV-1 Envs to advance as vaccine platforms.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41686912 · DOI · PMC13015429
Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Autoantibodies neutralizing type-I interferons (AAN-I-IFNs) emerge as global, common, and strong determinants of a growing number of severe viral diseases.
- Closing excerpt
- These findings support a model in which a germinal-center-derived memory B cell response directed against type-I IFNs is established before severe viral infection, providing a core mechanism linking T cell tolerance defect to pathogenic AAN-I-IFNs underlying severe viral diseases.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (151 words)
Autoantibodies neutralizing type-I interferons (AAN-I-IFNs) emerge as global, common, and strong determinants of a growing number of severe viral diseases. We report that AAN-I-IFNs+ patients with life-threatening COVID-19 pneumonia harbor circulating type-I IFN-specific B cells indistinguishable from patients bearing T cell tolerance defects of genetic origin. This autoimmune response mobilizes a highly diverse and stable circulating B cell response that is detected prior to severe viral infection and acquires high affinity and neutralization potential to type-I IFNs through extended somatic hypermutation. X-ray crystallography and AlphaFold3 structural analysis of hundreds of patient-derived monoclonal antibodies reveals the extended breadth of this response, targeting three major B cell epitopes covering all facets of type-I IFNs. These findings support a model in which a germinal-center-derived memory B cell response directed against type-I IFNs is established before severe viral infection, providing a core mechanism linking T cell tolerance defect to pathogenic AAN-I-IFNs underlying severe viral diseases.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42097138 · DOI · PMC13639993
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis [4]
- Research article Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity [5]
- Research article Opportunities and limitations of B cell depletion approaches in SLE [6]
- Research article B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases [7]
- Research article B cell immunometabolism in health and disease [8]
- Research article The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus [9]
References
- DeWitt WS, Vora AA, Araki T, Galloway JG, Alkutkar T, Bortolatto J, et al.. Replaying germinal center evolution on a quantified affinity landscape. . 2026. PMID 42248140 · DOI · PMC13360575
- Habib R, Roark RS, Li H, Connell AJ, Hogarty MP, Wagh K, et al.. Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development. . 2026. PMID 41686912 · DOI · PMC13015429
- Fournier M, Vanderkerken M, Dorgham K, Bastard P, Ahouzi O, Duquerroy S, et al.. Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections. . 2026. PMID 42097138 · DOI · PMC13639993
- Huang W, Berube J, McNamara M, Saksena S, Hartman M, Arshad T, et al.. Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis. Cytometry A. 2020. PMID 32542842 · DOI · PMC7323417
- Bemark M, Pitcher MJ, Dionisi C, Spencer J. Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity. Trends Immunol. 2024. PMID 38402045 · DOI · PMC11227984
- Stockfelt M, Teng YKO, Vital EM. Opportunities and limitations of B cell depletion approaches in SLE. Nat Rev Rheumatol. 2025. PMID 39815102 · DOI
- Haghikia A, Schett G, Mougiakakos D. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Lancet Neurol. 2024. PMID 38760099 · DOI
- Martinis E, Tonon S, Colamatteo A, La Cava A, Matarese G, Pucillo CEM. B cell immunometabolism in health and disease. Nat Immunol. 2025. PMID 39984733 · DOI
- Dörner T, Lipsky PE. The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2024. PMID 39511302 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.